The design is an analytical consecutive prospective multicenter study with an emerging cohort of patients with ACS through a National Registry in units of tertiary care in the IMSS (RENASCA IMSS). Follow-up will be done during hospitalization and 30 days, time of most Major Cardiovascular Events presentation (MACE) derived from the timing of initial treatment or lack of it.